CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-07-09 | Kummeth Charles R. Chief Executive Officer | Option exercise | +15,037 | $67.46 | $1.0M | 107,213 |
| 2019-07-09 | Kummeth Charles R. Chief Executive Officer | Sale | −15,037 | $212.43 | $3.2M | 92,176 |
| 2019-07-09 | Kummeth Charles R. Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −15,037 | 16,969 | ||
| 2019-07-08 | Kummeth Charles R. Chief Executive Officer | Option exercise | +17,994 | $67.46 | $1.2M | 110,170 |
| 2019-07-08 | Kummeth Charles R. Chief Executive Officer | Sale | −17,994 | $212.75 | $3.8M | 92,176 |
| 2019-07-08 | Kummeth Charles R. Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −17,994 | 32,006 | ||
| 2019-07-01 | VESSEY RUPERT Director | Grant or award · Stock Options (Right to Buy) | +588 | 588 | ||
| 2019-07-01 | VESSEY RUPERT Director | Grant or award | +147 | 147 | ||
| 2019-07-01 | VESSEY RUPERT Director | Grant or award · Stock Options (Right to buy) | +588 | 588 | ||
| 2019-06-12 | Eansor Norman David SVP - Novus Biologicals | Sale | −3,117 | $215.00 | $670K | 0 |
| 2019-06-04 | HIGGINS JOHN L Director | Option exercise | +5,000 | $63.03 | $315K | 8,526 |
| 2019-06-04 | HIGGINS JOHN L Director | Sale | −5,000 | $203.67 | $1.0M | 3,526 |
| 2019-06-04 | HIGGINS JOHN L Director | Option exercise · Stock Options (Right to buy) | −5,000 | 0 | ||
| 2019-05-24 | Furlow Brenda S. SVP - General Counsel | Option exercise | +5,400 | 7,589 | ||
| 2019-05-24 | Furlow Brenda S. SVP - General Counsel | Sale | −5,400 | $200.00 | $1.1M | 2,189 |
| 2019-05-24 | Furlow Brenda S. SVP - General Counsel | Option exercise · Stock Options (Right to buy) | +5,400 | 5,400 | ||
| 2019-05-01 | Kelderman Kim President, Diagnostics & Genom | Option exercise | +1,667 | $202.13 | $337K | 1,667 |
| 2019-05-01 | Kelderman Kim President, Diagnostics & Genom | Shares withheld for taxes | −844 | $202.13 | $171K | 823 |
| 2019-05-01 | Kelderman Kim President, Diagnostics & Genom | Option exercise · Restricted Stock | −1,667 | 0 | ||
| 2019-05-01 | Hippel James Chief Financial Officer | Option exercise | +35,000 | $86.25 | $3.0M | 39,382 |
Page 52 of 53 · 1,043 trades